Aandeel TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Takeda Pharmaceutical Company Limited Deutsche Boerse AG

Aandelen

TKD

JP3463000004

Geschatte realtime Tradegate
Andere beurzen
 16:48:11 17-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
24,6 EUR +1,05% Intraday-grafiek van Takeda Pharmaceutical Company Limited -1,31% -3,42%
15:21 Sectorupdate: Gezondheidszorgaandelen dalen premarket maandag MT
14:13 Ovid zoekt afstand van epilepsiemedicijn nadat Takeda rapporteert dat Fase 3 eindpunten niet gehaald zijn -- Pre-Bell aandelen dalen MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
Sector Update: Health Care Stocks Decline Premarket Monday
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
Takeda's seizure drug fails to meet main goal in late-stage studies
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen
TAKEDA PHARMACEUTICAL : Form 6 K
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 4502
  4. Koers TKD
  5. Nieuws Takeda Pharmaceutical Company Limited
  6. Andere talen